CN105394182A - Nutritional steamed stuffed bun with blood sugar reducing and heart and cerebral vessel health promoting efficacy - Google Patents
Nutritional steamed stuffed bun with blood sugar reducing and heart and cerebral vessel health promoting efficacy Download PDFInfo
- Publication number
- CN105394182A CN105394182A CN201510704379.9A CN201510704379A CN105394182A CN 105394182 A CN105394182 A CN 105394182A CN 201510704379 A CN201510704379 A CN 201510704379A CN 105394182 A CN105394182 A CN 105394182A
- Authority
- CN
- China
- Prior art keywords
- blood sugar
- effect
- cardiovascular
- nutrition bag
- lowering blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 54
- 239000008280 blood Substances 0.000 title claims abstract description 54
- 235000016709 nutrition Nutrition 0.000 title claims abstract description 37
- 230000036541 health Effects 0.000 title claims abstract description 21
- 230000001737 promoting effect Effects 0.000 title abstract description 3
- 230000002490 cerebral effect Effects 0.000 title abstract 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 24
- 235000021323 fish oil Nutrition 0.000 claims abstract description 15
- 239000000843 powder Substances 0.000 claims abstract description 15
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims abstract description 14
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims abstract description 14
- 235000010447 xylitol Nutrition 0.000 claims abstract description 14
- 239000000811 xylitol Substances 0.000 claims abstract description 14
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims abstract description 14
- 229960002675 xylitol Drugs 0.000 claims abstract description 14
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 13
- 239000011707 mineral Substances 0.000 claims abstract description 13
- 229940088594 vitamin Drugs 0.000 claims abstract description 13
- 229930003231 vitamin Natural products 0.000 claims abstract description 13
- 235000013343 vitamin Nutrition 0.000 claims abstract description 13
- 239000011782 vitamin Substances 0.000 claims abstract description 13
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims abstract description 12
- 229920001202 Inulin Polymers 0.000 claims abstract description 12
- CBOQJANXLMLOSS-UHFFFAOYSA-N ethyl vanillin Chemical compound CCOC1=CC(C=O)=CC=C1O CBOQJANXLMLOSS-UHFFFAOYSA-N 0.000 claims abstract description 12
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 12
- 229940029339 inulin Drugs 0.000 claims abstract description 12
- 229960003080 taurine Drugs 0.000 claims abstract description 12
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims abstract description 11
- JBYXPOFIGCOSSB-GOJKSUSPSA-N 9-cis,11-trans-octadecadienoic acid Chemical compound CCCCCC\C=C\C=C/CCCCCCCC(O)=O JBYXPOFIGCOSSB-GOJKSUSPSA-N 0.000 claims abstract description 10
- 229940108924 conjugated linoleic acid Drugs 0.000 claims abstract description 10
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims abstract description 10
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims abstract description 7
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 7
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 7
- 244000068988 Glycine max Species 0.000 claims abstract description 7
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 7
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000011777 magnesium Substances 0.000 claims abstract description 7
- 229910052749 magnesium Inorganic materials 0.000 claims abstract description 7
- 229940083466 soybean lecithin Drugs 0.000 claims abstract description 7
- 239000005913 Maltodextrin Substances 0.000 claims abstract description 6
- 229920002774 Maltodextrin Polymers 0.000 claims abstract description 6
- 229910000019 calcium carbonate Inorganic materials 0.000 claims abstract description 6
- 229940073505 ethyl vanillin Drugs 0.000 claims abstract description 6
- 239000000395 magnesium oxide Substances 0.000 claims abstract description 6
- 229940035034 maltodextrin Drugs 0.000 claims abstract description 6
- 235000020183 skimmed milk Nutrition 0.000 claims abstract description 6
- 235000013406 prebiotics Nutrition 0.000 claims abstract description 4
- 230000000694 effects Effects 0.000 claims description 35
- 230000035764 nutrition Effects 0.000 claims description 32
- 239000002131 composite material Substances 0.000 claims description 21
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 19
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 12
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 7
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 210000000582 semen Anatomy 0.000 claims description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 5
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 5
- 244000046052 Phaseolus vulgaris Species 0.000 claims description 5
- 235000010627 Phaseolus vulgaris Nutrition 0.000 claims description 5
- 239000005862 Whey Substances 0.000 claims description 5
- 102000007544 Whey Proteins Human genes 0.000 claims description 5
- 108010046377 Whey Proteins Proteins 0.000 claims description 5
- 239000011575 calcium Substances 0.000 claims description 5
- 229910052791 calcium Inorganic materials 0.000 claims description 5
- 229960000304 folic acid Drugs 0.000 claims description 5
- 235000019152 folic acid Nutrition 0.000 claims description 5
- 239000011724 folic acid Substances 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 5
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 4
- 230000036996 cardiovascular health Effects 0.000 claims description 4
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 3
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 3
- 235000019155 vitamin A Nutrition 0.000 claims description 3
- 239000011719 vitamin A Substances 0.000 claims description 3
- 229940045997 vitamin a Drugs 0.000 claims description 3
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 2
- 229930003268 Vitamin C Natural products 0.000 claims description 2
- 229930003427 Vitamin E Natural products 0.000 claims description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 2
- 229910052742 iron Inorganic materials 0.000 claims description 2
- 229960003512 nicotinic acid Drugs 0.000 claims description 2
- 235000001968 nicotinic acid Nutrition 0.000 claims description 2
- 239000011664 nicotinic acid Substances 0.000 claims description 2
- 229940055726 pantothenic acid Drugs 0.000 claims description 2
- 235000019161 pantothenic acid Nutrition 0.000 claims description 2
- 239000011713 pantothenic acid Substances 0.000 claims description 2
- 235000019154 vitamin C Nutrition 0.000 claims description 2
- 239000011718 vitamin C Substances 0.000 claims description 2
- 229940046009 vitamin E Drugs 0.000 claims description 2
- 235000019165 vitamin E Nutrition 0.000 claims description 2
- 239000011709 vitamin E Substances 0.000 claims description 2
- 239000011701 zinc Substances 0.000 claims description 2
- 229910052725 zinc Inorganic materials 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 16
- 206010020772 Hypertension Diseases 0.000 abstract description 9
- 235000012000 cholesterol Nutrition 0.000 abstract description 9
- 235000019197 fats Nutrition 0.000 abstract description 9
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract description 3
- 235000012054 meals Nutrition 0.000 abstract description 3
- -1 phytosterol Chemical compound 0.000 abstract description 3
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 abstract 2
- 229940107187 fructooligosaccharide Drugs 0.000 abstract 2
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 abstract 2
- 102000004407 Lactalbumin Human genes 0.000 abstract 1
- 108090000942 Lactalbumin Proteins 0.000 abstract 1
- 244000302512 Momordica charantia Species 0.000 abstract 1
- 235000009811 Momordica charantia Nutrition 0.000 abstract 1
- 235000009812 Momordica cochinchinensis Nutrition 0.000 abstract 1
- 235000018365 Momordica dioica Nutrition 0.000 abstract 1
- 240000002853 Nelumbo nucifera Species 0.000 abstract 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 abstract 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 abstract 1
- 108010073771 Soybean Proteins Proteins 0.000 abstract 1
- 210000004204 blood vessel Anatomy 0.000 abstract 1
- 150000001841 cholesterols Chemical class 0.000 abstract 1
- 230000036449 good health Effects 0.000 abstract 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 abstract 1
- 235000019710 soybean protein Nutrition 0.000 abstract 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 24
- 235000013325 dietary fiber Nutrition 0.000 description 13
- 239000008103 glucose Substances 0.000 description 11
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- 235000010755 mineral Nutrition 0.000 description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- 239000003925 fat Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 7
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 6
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 6
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 6
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 6
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 6
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 102000004877 Insulin Human genes 0.000 description 5
- 108090001061 Insulin Proteins 0.000 description 5
- 230000002218 hypoglycaemic effect Effects 0.000 description 5
- 229940125396 insulin Drugs 0.000 description 5
- 108010010234 HDL Lipoproteins Proteins 0.000 description 4
- 102000015779 HDL Lipoproteins Human genes 0.000 description 4
- 108010007622 LDL Lipoproteins Proteins 0.000 description 4
- 102000007330 LDL Lipoproteins Human genes 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 3
- 208000001953 Hypotension Diseases 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 229960002104 cyanocobalamin Drugs 0.000 description 3
- 235000000639 cyanocobalamin Nutrition 0.000 description 3
- 239000011666 cyanocobalamin Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000011706 ferric diphosphate Substances 0.000 description 3
- 235000007144 ferric diphosphate Nutrition 0.000 description 3
- CADNYOZXMIKYPR-UHFFFAOYSA-B ferric pyrophosphate Chemical compound [Fe+3].[Fe+3].[Fe+3].[Fe+3].[O-]P([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])([O-])=O CADNYOZXMIKYPR-UHFFFAOYSA-B 0.000 description 3
- 229940036404 ferric pyrophosphate Drugs 0.000 description 3
- 208000021822 hypotensive Diseases 0.000 description 3
- 230000001077 hypotensive effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 229960003966 nicotinamide Drugs 0.000 description 3
- 235000005152 nicotinamide Nutrition 0.000 description 3
- 239000011570 nicotinamide Substances 0.000 description 3
- 230000000291 postprandial effect Effects 0.000 description 3
- 235000019192 riboflavin Nutrition 0.000 description 3
- 229960002477 riboflavin Drugs 0.000 description 3
- 239000002151 riboflavin Substances 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- UIERGBJEBXXIGO-UHFFFAOYSA-N thiamine mononitrate Chemical compound [O-][N+]([O-])=O.CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N UIERGBJEBXXIGO-UHFFFAOYSA-N 0.000 description 3
- 229940042585 tocopherol acetate Drugs 0.000 description 3
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 3
- 229960001763 zinc sulfate Drugs 0.000 description 3
- 229910000368 zinc sulfate Inorganic materials 0.000 description 3
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- 208000032928 Dyslipidaemia Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 235000021152 breakfast Nutrition 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- OILXMJHPFNGGTO-NRHJOKMGSA-N Brassicasterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@](C)([C@H]([C@@H](/C=C/[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 OILXMJHPFNGGTO-NRHJOKMGSA-N 0.000 description 1
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 description 1
- 206010019273 Heart disease congenital Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- OILXMJHPFNGGTO-ZRUUVFCLSA-N UNPD197407 Natural products C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)C=C[C@H](C)C(C)C)[C@@]1(C)CC2 OILXMJHPFNGGTO-ZRUUVFCLSA-N 0.000 description 1
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 210000000593 adipose tissue white Anatomy 0.000 description 1
- 230000000489 anti-atherogenic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- OILXMJHPFNGGTO-ZAUYPBDWSA-N brassicasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@H](C)C(C)C)[C@@]1(C)CC2 OILXMJHPFNGGTO-ZAUYPBDWSA-N 0.000 description 1
- 235000004420 brassicasterol Nutrition 0.000 description 1
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 description 1
- 235000000431 campesterol Nutrition 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 230000005961 cardioprotection Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- 230000002079 cooperative effect Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 150000001993 dienes Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 235000020667 long-chain omega-3 fatty acid Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000010197 meta-analysis Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 1
- 235000016831 stigmasterol Nutrition 0.000 description 1
- 229940032091 stigmasterol Drugs 0.000 description 1
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000021092 sugar substitutes Nutrition 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/156—Flavoured milk preparations ; Addition of fruits, vegetables, sugars, sugar alcohols or sweeteners
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The invention discloses a nutritional steamed stuffed bun with blood sugar reducing and heart and cerebral vessel health promoting efficacy. The nutritional steamed stuffed bun contains, by mass, 4-6% of isomaltooligosaccharide, 2.4-3.6% of fructooligosaccharide and 2.4-3.6% of inulin. The nutritional steamed stuffed bun also contains instant soybean powder, skimmed milk powder, maltodextrin, xylitol, lactalbumin powder, isolated soybean protein meal, phytosterol, soybean lecithin, conjugated linoleic acid glyceride, balsam pear extract, lotus seed extract, cassia seed extract, fish oil, calcium carbonate, magnesium oxide, compounded vitamins, compounded mineral matters and ethyl vanillin. Prebiotics (isomaltooligosaccharide, fructooligosaccharide and inulin), xylitol, phytosterol, conjugated linoleic acid glyceride, fish oil, taurine and magnesium are added to the nutritional steamed stuffed bun to reduce the concentration of cholesterols in blood of people with diabetes, hypertension and hyperlipaemia, reduce the blood sugar and fat level and promote healthiness of heart and blood vessels.
Description
Technical field
The present invention relates to a kind of nutrition bag that there is effect of lowering blood sugar and promote cardiovascular and cerebrovascular health.
Background technology
Chronic cardiovascular disease when hypertension, high fat of blood, diabetes, China >=18 year old crowd's Prevalence of Hypertension is 18.8% according to statistics, and the wherein male sex 20.2%, women 18.0%.In mid-aged population, the area that the level of economic development is higher, Prevalence of Hypertension is higher, and graded is comparatively obvious, and Hypertension raises gradually with age growth.China >=18 year old crowd's diabetes prevalence is 2.6%, and wherein the male sex is 2.5%, and women is 2.7%, and diabetes prevalence is all along with the increase at age raises gradually, and the Urban population rate of climb is faster.Metropolitan diabetes prevalence, apparently higher than other areas, is secondly small and medium-sized cities.China >=18 year old crowd's hypercholesterolemia, hypertriglyceridemia, Low high-density lipoprotein cholesterol illness rate are followed successively by 2.9%, 11.9%, 7.4%; total dyslipidemia illness rate reaches 18.6%; hypercholesterolemia illness rate increased with the age to be had and increases trend gradually, and this trend of women is comparatively obvious.Old women illness rate is apparently higher than the male sex.It can thus be appreciated that China's hypertension, high fat of blood and Prevalence of Diabetes situation allow of no optimist, in the elderly, especially Urban population, the people of 1/3 ~ 1/2 suffers from hypertension, and the people of nearly 1/10 suffers from diabetes, separately have the artificial potential danger crowd of nearly 1/10, the people of nearly 30% has dyslipidemia.
Large quantity research proves, dietary fiber can not be digested in human gastrointestinal tract, but can SCFA be fermented into, thus the synthesis of triglycerides in minimizing liver, reduce blood lipid level and alimentary canal chymeviscosity can be made to enlarge markedly, make metabolism of lipid and cholesterol in daily ration digest and assimilate minimizing, also can reduce insulin and glucose level in body blood plasma, thus play hypoglycemic effect.Oligoisomaltose, FOS and inulin as common dietary fiber, also usually for auxiliary hyperglycemic, blood fat and blood pressure.But, being used alone a kind of dietary fiber needs very large amount just can reach this effect usually, and a large amount of dietary fiber add stability, the mouthfeel that can affect modulation dairy products, particularly when consumer is more and more unwilling to use a large amount of additive, the existence of dietary fiber also usually can bring the misunderstanding of consumer.Therefore, it is composite that inventor finds by the fiber to meals unexpectedly, can not improve dietary fiber consumption, even reduces it when using total amount, still reach good, than the effect being used alone the better hypoglycemic of a kind of product, hypotensive and reducing blood lipid.
Xylitol, as a kind of functional natural sweetener, can participate in carbohydate metabolism in human body, after entering blood, insulin is not needed to drop into cell, and accretion rate is fast, blood glucose value can not be caused to raise, be suitable for the trophism sugar substitute of diabetes patient.Due to the special biochemical action of xylitol, application is increasingly extensive at present, and Xylitol injection etc. are in clinical practice.Multinomially on the research of the impact that diabetes B patient blood glucose fluctuate, the blood glucose fluctuation of Xylitol injection to diabetes B patient is shown to assessment Xylitol injection have no significant effect, and can Islet Cells Insulin secretion be stimulated, without the bad reaction of liver kidney.
Phytosterol is a kind of active component in plant, is extensively present in each vegetable oil, nut and vegetable seeds, is also present in other plant food as in vegetable and fruit.Natural phytosterin is of a great variety, mainly comprises cupreol, stigmasterol, brassicasterol and campesterol four kinds of demethlyate sterols.Phytosterol can reducing blood lipid, reduce heart disease rate and pre-anti-cancer etc., its topmost effect reduces the level of cholesterol in serum, be our times steroid drugs in the urgent need to important medicine source.The rising of cholesterol in serum level is the hazards causing coronary heart disease.Most method reducing cholesterol in serum level, needs Tighter control and depends on medicine.The function that the mankind are familiar with phytosterol is the earliest from its research reducing blood cholesterol level.Much research proves, supplementary phytosterol obviously can reduce T-CHOL in blood (TC) and low-density lipoprotein (LDL) content, and do not reduce HDL (HDL) and content of triglyceride, LDL/HDL ratio is reduced, and without any obvious side effect.U.S. FDA makes statement according to research report, and the phytosterin ester at least taking in 1.3g every day just can play the effect reducing cholesterol.
CLA (CLA) is the multiple position of the conjugated diene of essential fatty acids linoleic derivative and the general name of steric isomer, and CLA is as a kind of novel aliphatic acid, and its physiological function is gradually by people are admitted.CLA can prevent fat and blood platelet from depositing on atherosclerotic pathology arterial wall; thus antiatherogenic effect can be played; its effect is linoleic 5 times, and CLA can also reduce the cholesterol level in blood and reduce the propagation of aliphatic acid in liver and white adipose tissue and the level of triacylglycerol ester.There are some researches show that CLA can effectively reduce patients with hypothyroidism's cholesterol and triglyceride level.Separately there are the body weight and the serum leptin level significant correlation that about conjugated linoleic acid glyceride, the research of the impact of diabetes B are shown to CLA and diabetes B patient.
Fish main body of oil is triglyceride, vitamin A and D, phosphatide, glyceride, steroids etc., and the difference of fish oil and general andvegetable fats is that it contains longer carbochain and degree of unsaturation.In fish oil ω-3 long-chain polyunsaturated fatty acid and eicosapentaenoic acid (EPA) and DHA (DHA) content higher, be the trophic factors with different physiological roles.Great many of experiments shows, fish oil has obvious blood fat reducing function, and it can play the effect reducing serum triglyceride, T-CHOL, low-density lipoprotein, VLDL and increasing serum HDL.The mechanism of fish oil DHA and EPA effect for reducing blood fat promotes Cholesterol Excretion, suppresses the synthesis of endogenous cholesterol, changes the composition of aliphatic acid in lipoprotein, thus increase the mobility of lipoprotein, reduces the synthesis of the triglycerides in VLDL.Fish oil DHA and EPA can also suppress platelet aggregation, reduce thromboxane and are formed, have the function of prevention miocardial infarction.
Taurine be in-vivo content the abundantest containing sulfonic group-amino acid; be present in the various tissue of human body in a free form; do not participate in the synthesis of protein; taurine has biological action widely; as: maintain normal visual performance and retinal structure; contribute to cardiovascular health, can be used as a kind of CNS inhibition neurotransmitter and regulate the excitability etc. of central nervous system, be widely used at present clinical in.Taurine is free amino acid the abundantest in heart, accounts for more than 50% of free amino acid total amount, taurine can available protecting cardiac muscle cell and avoid occur heart malformations, have the effect reduced blood pressure simultaneously.To a certain extent, taurine is that the cross-film by affecting calcium ion flows and has an effect to heart cell, eliminate the negative effect that calcium ion in heart is too much or lack, thus cardioprotection tissue escapes injury.
Trace element magnesium contributes to the secretion regulating insulin to a certain extent, contribute to strengthening insulin to the reactivity of glucose, and contribute to reducing cell to the opposing degree of insulin, China has scholar's meta-analysis to find to there is remarkable negative correlation between magnesium absorption height and diabetes B occurrence risk, and therefore pathoglycemia crowd should strengthen the absorption of magnesium.
The present invention can help diabetes, hypertension, people with hyperlipidemia to reduce Blood Cholesterol concentration, reduces blood pressure and blood lipoid level, promotes cardiovascular health.
Composite by soluble dietary fiber of the present invention, obtains that a kind of cost is low, product stable, taste is good, is easy to the effect of lowering blood sugar that consumer accepts and the nutrition bag promoting cardiovascular and cerebrovascular health.Test proves, composite by the fiber to meals can not improve dietary fiber consumption, even reduces it when using total amount, still reaches good, even than the effect being used alone the better hypoglycemic of a kind of product, hypotensive and reducing blood lipid.
Summary of the invention
Its object of the present invention is just to provide a kind of nutrition bag having effect of lowering blood sugar and promote cardiovascular and cerebrovascular health.
The technical scheme taked for achieving the above object is: a kind of nutrition bag having effect of lowering blood sugar and promote cardiovascular and cerebrovascular health, this nutrition bag is formed by following raw materials according mixture: instant bean 18% ~ 27%(refers to mass percentage, lower same), skimmed milk powder 14.5% ~ 21.5%, maltodextrin 14% ~ 21%, xylitol 8.5% ~ 11.5%, oligoisomaltose 4% ~ 6%, FOS 2.4% ~ 3.6%, inulin 2.4% ~ 3.6%, PURE WHEY 4.5% ~ 7.0%, soybean isolate protein powder 3.5% ~ 5.5%, phytosterol 1.0% ~ 3.2%, soybean lecithin 0.5% ~ 2.5%, conjugated linoleic acid glyceride 1.0% ~ 1.5%, Bitter Melon P.E 0.8% ~ 1.2%, Semen Nelumbinis extract 0.8% ~ 1.2%, cassia seed extract 0.8% ~ 1.2%, fish oil 0.4% ~ 0.6%, calcium carbonate 0.50% ~ 0.70%, magnesia 2.0% ~ 3.0%, composite vitamin 0.40% ~ 0.60%, composite mineral matter 0.08% ~ 0.12%, Ethyl vanillin 0.015% ~ 0.025%.
Above-mentioned a kind of nutrition bag that there is effect of lowering blood sugar and promote cardiovascular and cerebrovascular health, DHA content >=36mg/g, EPA content >=27mg/g, EPA+DHA content >=144mg/g in described fish oil powder.
Above-mentioned a kind of nutrition bag having effect of lowering blood sugar and promote cardiovascular and cerebrovascular health, this nutrition comprises oligoisomaltose, FOS, inulin three kinds of prebioticses, and three kinds of prebiotics adding proportions are 1.67:1:1.
Above-mentioned a kind of nutrition bag that there is effect of lowering blood sugar and promote cardiovascular and cerebrovascular health, this nutrition includes a certain amount of vitamin, and in 100 grams of nutrition bags, its vitamin contained comprises: vitamin A 600 μ g ~ 1700 μ g, vitamin E 7.6mg ~ 18mg, Cobastab
10.96mg ~ 2.20mg, Cobastab
20.96mg ~ 2.20mg, Cobastab
60.72mg ~ 2.20mg, Cobastab
121.0 μ g ~ 6.6 μ g, vitamin C 100mg ~ 225mg, nicotinic acid 11mg ~ 33mg, folic acid 280 μ g ~ 600 μ g, pantothenic acid 3.2mg ~ 8.0mg, taurine 110mg ~ 140mg.
Above-mentioned a kind of nutrition bag having effect of lowering blood sugar and promote cardiovascular and cerebrovascular health, also containing a certain amount of mineral matter in this nutrition bag, in 100 grams of nutrition bags, its mineral matter contained comprises: calcium 320mg ~ 1000mg, iron 9.6mg ~ 22mg, zinc 7.2mg ~ 18mg, magnesium 130mg ~ 210mg.
It is composite that inventor finds by dietary fiber unexpectedly, dietary fiber consumption can not improved, even reduce it when using total amount, still reach good, and than being used alone effect of the better hypoglycemic of a kind of dietary fiber, hypotensive and reducing blood lipid.Simultaneously; by dietary fiber and xylitol, phytosterol, conjugated linoleic acid glyceride, fish oil, taurine and magnesium with the use of; obtain one and effectively can reduce Blood Cholesterol concentration at help diabetes, hypertension, people with hyperlipidemia; reduce blood pressure and blood lipoid level, promote the nutrition bag of cardiovascular health.Meanwhile, these nutrition product of contracting for fixed output quotas have that cost is low, emulsification property good, mobility after bath is moderate, good stability, taste good, are easy to consumer and the significantly beneficial effect such as accept.
Detailed description of the invention
The present embodiment is only illustrative, should be understood that the present invention not by the restriction of these embodiments.
Embodiment 1
Have a nutrition bag for effect of lowering blood sugar and promotion cardiovascular and cerebrovascular health, in 1000kg ± 2kg, it is formed by following raw materials according mixture:
Instant bean 230kg
Skimmed milk powder 160kg
Maltodextrin 192kg or 192.2kg
Xylitol 90kg
Oligoisomaltose 50kg or 50.1kg
FOS 30kg
Inulin 30kg
PURE WHEY 60kg
Soybean isolate protein powder 55kg
Phytosterol 30kg
Soybean lecithin 15kg
Conjugated linoleic acid glyceride 12kg
Bitter Melon P.E 8kg
Semen Nelumbinis extract 10kg
Cassia seed extract 8kg
Fish oil 5kg
Calcium carbonate 6kg
Magnesia 2.5kg
Composite vitamin 5.0kg
Composite mineral matter 1.0kg
Ethyl vanillin 0.2kg
Wherein composite vitamin is containing axerophtholum aceticum 85.0g, dl-α-D-α-tocopherol acetate 411.0g, Thiamin mononitrate 18g; riboflavin 10g; puridoxine hydrochloride 13g, hydrochloric acid cyanocobalamin 16g, L-AA sodium 1.62kg; niacinamide 144g; folic acid 39g, D-VB5 calcium 42.1g, taurine 1.255kg; composite mineral matter is containing ferric pyrophosphate 594g, zinc sulfate 272g.
Embodiment 2
Have a nutrition bag for effect of lowering blood sugar and promotion cardiovascular and cerebrovascular health, in 1000kg ± 2kg, it is formed by following raw materials according mixture.
Instant bean 250kg
Skimmed milk powder 200kg
Maltodextrin 147kg or 146.95kg
Xylitol 100kg
Oligoisomaltose 40kg
FOS 32kg
Inulin 30kg
PURE WHEY 50kg
Soybean isolate protein powder 45kg
Phytosterol 25kg
Soybean lecithin 18kg
Conjugated linoleic acid glyceride 15kg
Bitter Melon P.E 9kg
Semen Nelumbinis extract 8kg
Cassia seed extract 10kg
Fish oil 5.5kg
Calcium carbonate 6.5kg
Magnesia 2.8kg
Composite vitamin 5.0kg
Composite mineral matter 1.0kg
Ethyl vanillin 0.25kg
Wherein composite vitamin is containing axerophtholum aceticum 85.0g, dl-α-D-α-tocopherol acetate 411.0g, Thiamin mononitrate 18g; riboflavin 10g; puridoxine hydrochloride 13g, hydrochloric acid cyanocobalamin 16g, L-AA sodium 1.62kg; niacinamide 144g; folic acid 39g, D-VB5 calcium 42.1g, taurine 1.255kg; composite mineral matter is containing ferric pyrophosphate 594g, zinc sulfate 272g.
Embodiment 3
Have a nutrition bag for effect of lowering blood sugar and promotion cardiovascular and cerebrovascular health, in 1000kg ± 2kg, it is formed by following raw materials according mixture:
Instant bean 225kg
Skimmed milk powder 185kg
Maltodextrin 153kg or 153.15kg
Xylitol 105kg
Oligoisomaltose 55kg
FOS 32kg
Inulin 28kg
PURE WHEY 65kg
Soybean isolate protein powder 40kg
Phytosterol 28kg
Soybean lecithin 20kg
Conjugated linoleic acid glyceride 15kg
Bitter Melon P.E 10kg
Semen Nelumbinis extract 8kg
Cassia seed extract 10kg
Fish oil 6kg
Calcium carbonate 6.5kg
Magnesia 2.2kg
Composite vitamin 5.0kg
Composite mineral matter 1.0kg
Ethyl vanillin 0.15kg
Wherein composite vitamin is containing axerophtholum aceticum 85.0g, dl-α-D-α-tocopherol acetate 411.0g, Thiamin mononitrate 18g; riboflavin 10g; puridoxine hydrochloride 13g, hydrochloric acid cyanocobalamin 16g, L-AA sodium 1.62kg; niacinamide 144g; folic acid 39g, D-VB5 calcium 42.1g, taurine 1.255kg; composite mineral matter is containing ferric pyrophosphate 594g, zinc sulfate 272g.
Below by concrete test, further illustrate product of the present invention for hypoglycemic impact, to prove excellent effect of the present invention.
(1) test method
1, research object
Experiment patient clarifies a diagnosis to meet the outpatient 45 of WHO diabetes diagnostic criterion, the course of disease 4 ~ 18 years, the wherein male sex 31 people, women 14 people, 36 ~ 80 years old age, average 59 years old.Patient is divided into four groups at random, wherein 1-3 group breakfast every day uses the semi-solid products (as congee, soya-bean milk etc.) in products substitution breakfast of 50g embodiment of the present invention 1-3, control group takes the product (formula of employing embodiment 1 that 50g transforms according to embodiment 1, only add inulin and change 110kg into, simultaneously, do not add FOS and oligoisomaltose), at the first day of experiment, after experiment two weeks, experiment afterwards surrounding respectively experimenter is checked UP and blood sugar, glucose in urine, blood lipids index mensuration.Blood sugar Johnson & Johnson's blood glucose meter measures; Glucose in urine is by dry test paper method; Blood fat enzymatic reaction method.
(2) interpretation of result
The change (M ± SD) of front and back experimental subjects fasting blood-glucose, postprandial blood sugar tested by table 1
Note: * represents P<0.05; * represents P<0.01.
As shown in Table 1, between 1-3 group, have notable difference than before experiment after experiment, no matter particularly take the subject of this product embodiments 1, after 4 weeks, be its fasting blood-glucose, or postprandial blood sugar, all reaches the level of pole significant difference.And although control group is also variant, its fasting blood-glucose does not reach significant difference level, and the change of its postprandial blood sugar is also only significant difference.Result shows, composite by dietary fiber of the present invention, create obvious cooperative effect between three, blood sugar decreasing effect is better.
Claims (8)
1. there is a nutrition bag for effect of lowering blood sugar and promotion cardiovascular and cerebrovascular health, it is characterized in that the composition containing, for example lower mass percentage (lower same): oligoisomaltose 4% ~ 6%, FOS 2.4% ~ 3.6%, inulin 2.4% ~ 3.6%.
2. there is the nutrition bag of effect of lowering blood sugar and promotion cardiovascular and cerebrovascular health as claimed in claim 1, it is characterized in that also containing: xylitol 8.5% ~ 11.5%, phytosterol 1.0% ~ 3.2%, soybean lecithin 0.5% ~ 2.5%, conjugated linoleic acid glyceride 1.0% ~ 1.5%.
3. there is the nutrition bag of effect of lowering blood sugar and promotion cardiovascular and cerebrovascular health as claimed in claim 1, it is characterized in that also containing: Bitter Melon P.E 0.8% ~ 1.2%, Semen Nelumbinis extract 0.8% ~ 1.2%, cassia seed extract 0.8% ~ 1.2%.
4. there is the nutrition bag of effect of lowering blood sugar and promotion cardiovascular and cerebrovascular health as claimed in claim 1, it is characterized in that being formed by following raw materials according mixture: instant bean 18% ~ 27%(refers to mass percentage, lower same), skimmed milk powder 14.5% ~ 21.5%, maltodextrin 14% ~ 21%, xylitol 8.5% ~ 11.5%, oligoisomaltose 4% ~ 6%, FOS 2.4% ~ 3.6%, inulin 2.4% ~ 3.6%, PURE WHEY 4.5% ~ 7.0%, soybean isolate protein powder 3.5% ~ 5.5%, phytosterol 1.0% ~ 3.2%, soybean lecithin 0.5% ~ 2.5%, conjugated linoleic acid glyceride 1.0% ~ 1.5%, Bitter Melon P.E 0.8% ~ 1.2%, Semen Nelumbinis extract 0.8% ~ 1.2%, cassia seed extract 0.8% ~ 1.2%, fish oil 0.4% ~ 0.6%, calcium carbonate 0.50% ~ 0.70%, magnesia 2.0% ~ 3.0%, composite vitamin 0.40% ~ 0.60%, composite mineral matter 0.08% ~ 0.12%, Ethyl vanillin 0.015% ~ 0.025%.
5. a kind of nutrition bag having effect of lowering blood sugar and promote cardiovascular and cerebrovascular health according to claim 4, is characterized in that DHA content >=36mg/g in described fish oil powder, EPA content >=27mg/g, EPA+DHA content >=144mg/g.
6. a kind of as claimed in claim 1 have effect of lowering blood sugar and promote the nutrition bag of cardiovascular health, it is characterized in that the adding proportion of oligoisomaltose, FOS, inulin three kinds of prebioticses is 1.67:1:1.
7. a kind of nutrition bag that there is effect of lowering blood sugar and promote cardiovascular and cerebrovascular health as claimed in claim 1, it is characterized in that in described nutrition bag also containing a certain amount of vitamin, in 100 grams of nutrition bags, its vitamin contained comprises: vitamin A 600 μ g ~ 1700 μ g, vitamin E 7.6mg ~ 18mg, Cobastab
10.96mg ~ 2.20mg, Cobastab
20.96mg ~ 2.20mg, Cobastab
60.72mg ~ 2.20mg, Cobastab
121.0 μ g ~ 6.6 μ g, vitamin C 100mg ~ 225mg, nicotinic acid 11mg ~ 33mg, folic acid 280 μ g ~ 600 μ g, pantothenic acid 3.2mg ~ 8.0mg, taurine 110mg ~ 140mg.
8. a kind of nutrition bag that there is effect of lowering blood sugar and promote cardiovascular and cerebrovascular health as claimed in claim 1, it is characterized in that in described nutrition bag also containing a certain amount of mineral matter, in 100 grams of nutrition bags, its mineral matter contained comprises: calcium 320mg ~ 1000mg, iron 9.6mg ~ 22mg, zinc 7.2mg ~ 18mg, magnesium 130mg ~ 210mg.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510704379.9A CN105394182A (en) | 2015-10-27 | 2015-10-27 | Nutritional steamed stuffed bun with blood sugar reducing and heart and cerebral vessel health promoting efficacy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510704379.9A CN105394182A (en) | 2015-10-27 | 2015-10-27 | Nutritional steamed stuffed bun with blood sugar reducing and heart and cerebral vessel health promoting efficacy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105394182A true CN105394182A (en) | 2016-03-16 |
Family
ID=55460232
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510704379.9A Pending CN105394182A (en) | 2015-10-27 | 2015-10-27 | Nutritional steamed stuffed bun with blood sugar reducing and heart and cerebral vessel health promoting efficacy |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105394182A (en) |
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105918468A (en) * | 2016-05-04 | 2016-09-07 | 黑龙江飞鹤乳业有限公司 | Modified milk powder composition with effect of stabilizing blood glucose and preparation method thereof |
| CN105942498A (en) * | 2016-05-05 | 2016-09-21 | 上海诗琳美生物科技有限公司 | Functional nutritional food compounds with diabetes-treating effects and preparation methods thereof |
| CN106072533A (en) * | 2016-06-18 | 2016-11-09 | 江苏阜丰生物科技有限公司 | A kind of full nutritional formulas of diabetes patients |
| CN106106740A (en) * | 2016-06-22 | 2016-11-16 | 仕承生物工程（上海）有限公司 | A kind of compositions reducing three-hypers disease |
| CN106261442A (en) * | 2016-09-26 | 2017-01-04 | 孙克明 | A kind of Radix Et Rhizoma Fagopyri Tatarici cocoa solids beverage with health care and preparation method thereof |
| CN106418524A (en) * | 2016-09-30 | 2017-02-22 | 黑龙江省康平生物工程有限责任公司 | Health care product capable of preventing hyperglycemia and preparation method of health care product |
| CN106509126A (en) * | 2016-10-25 | 2017-03-22 | 郑州福润德食品有限公司 | Solid drink having weight losing and body slimming functions |
| CN108635516A (en) * | 2018-05-15 | 2018-10-12 | 深圳市鑫永康生物技术开发有限公司 | A kind of formula and preparation method thereof adjusting blood glucose, blood fat particle electuary |
| CN108850913A (en) * | 2018-06-04 | 2018-11-23 | 山东龙力生物科技股份有限公司 | One kind special medicine purposes formula food of diabetes containing prebiotics and preparation method thereof |
| CN110432500A (en) * | 2019-08-07 | 2019-11-12 | 武汉英纽林生物科技有限公司 | A kind of prebiotic compositions and preparation method and purposes containing inulin |
| CN112042753A (en) * | 2020-09-16 | 2020-12-08 | 甘肃华羚乳品股份有限公司 | Modified milk powder suitable for diabetes patients and preparation method thereof |
| CN113508841A (en) * | 2021-07-09 | 2021-10-19 | 遂宁市生岁食用植物油有限公司 | Nutritious morning tea |
| CN113575694A (en) * | 2021-07-15 | 2021-11-02 | 黑龙江谱华威乳业集团有限公司 | Low-fat modified milk powder containing composition for assisting in reducing blood fat and lowering blood pressure |
| CN113951328A (en) * | 2021-11-30 | 2022-01-21 | 北安宜品努卡乳业有限公司 | A nutritional food for lowering blood sugar and reducing blood lipid, and its preparation method |
| CN114145457A (en) * | 2021-12-10 | 2022-03-08 | 黑龙江飞鹤乳业有限公司 | Hypoglycemic composition |
| CN116420875A (en) * | 2023-02-06 | 2023-07-14 | 黑龙江飞鹤乳业有限公司 | Nutritional composition for assisting blood lipid regulation and cardiovascular and cerebrovascular health |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101971884A (en) * | 2010-09-10 | 2011-02-16 | 甘肃岷归中药材科技有限公司 | Micron Chinese angelica and Astragalus membranaceus instant soybean milk powder and preparation method thereof |
| CN102356780A (en) * | 2011-09-22 | 2012-02-22 | 魏牧 | Instant soymilk powder able to clear away heart-fire and nourish blood, supplement center and boost qi as well as processing method thereof |
| CN102860449A (en) * | 2012-09-10 | 2013-01-09 | 广东省农业科学院农业生物技术研究所 | Total nutrient meal suitable for being eaten by patients suffering from tumor and preparation method thereof |
| CN103190630A (en) * | 2013-04-19 | 2013-07-10 | 广东太阳神集团有限公司 | Functional protein powder containing conjugated linoleic acid glycerides |
| CN104000216A (en) * | 2014-05-14 | 2014-08-27 | 河南泰利杰生物科技有限公司 | Prebiotics water-soluble dietary fiber and preparation method thereof |
| CN104256255A (en) * | 2014-10-08 | 2015-01-07 | 保龄宝生物股份有限公司 | Granular functional sugar and preparation method thereof |
| CN104413334A (en) * | 2013-08-30 | 2015-03-18 | 深圳华大基因科技有限公司 | Edible composition as well as preparation method and application thereof |
-
2015
- 2015-10-27 CN CN201510704379.9A patent/CN105394182A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101971884A (en) * | 2010-09-10 | 2011-02-16 | 甘肃岷归中药材科技有限公司 | Micron Chinese angelica and Astragalus membranaceus instant soybean milk powder and preparation method thereof |
| CN102356780A (en) * | 2011-09-22 | 2012-02-22 | 魏牧 | Instant soymilk powder able to clear away heart-fire and nourish blood, supplement center and boost qi as well as processing method thereof |
| CN102860449A (en) * | 2012-09-10 | 2013-01-09 | 广东省农业科学院农业生物技术研究所 | Total nutrient meal suitable for being eaten by patients suffering from tumor and preparation method thereof |
| CN103190630A (en) * | 2013-04-19 | 2013-07-10 | 广东太阳神集团有限公司 | Functional protein powder containing conjugated linoleic acid glycerides |
| CN104413334A (en) * | 2013-08-30 | 2015-03-18 | 深圳华大基因科技有限公司 | Edible composition as well as preparation method and application thereof |
| CN104000216A (en) * | 2014-05-14 | 2014-08-27 | 河南泰利杰生物科技有限公司 | Prebiotics water-soluble dietary fiber and preparation method thereof |
| CN104256255A (en) * | 2014-10-08 | 2015-01-07 | 保龄宝生物股份有限公司 | Granular functional sugar and preparation method thereof |
Cited By (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105918468A (en) * | 2016-05-04 | 2016-09-07 | 黑龙江飞鹤乳业有限公司 | Modified milk powder composition with effect of stabilizing blood glucose and preparation method thereof |
| CN105942498A (en) * | 2016-05-05 | 2016-09-21 | 上海诗琳美生物科技有限公司 | Functional nutritional food compounds with diabetes-treating effects and preparation methods thereof |
| CN106072533A (en) * | 2016-06-18 | 2016-11-09 | 江苏阜丰生物科技有限公司 | A kind of full nutritional formulas of diabetes patients |
| CN106106740A (en) * | 2016-06-22 | 2016-11-16 | 仕承生物工程（上海）有限公司 | A kind of compositions reducing three-hypers disease |
| CN106261442A (en) * | 2016-09-26 | 2017-01-04 | 孙克明 | A kind of Radix Et Rhizoma Fagopyri Tatarici cocoa solids beverage with health care and preparation method thereof |
| CN106418524A (en) * | 2016-09-30 | 2017-02-22 | 黑龙江省康平生物工程有限责任公司 | Health care product capable of preventing hyperglycemia and preparation method of health care product |
| CN106509126A (en) * | 2016-10-25 | 2017-03-22 | 郑州福润德食品有限公司 | Solid drink having weight losing and body slimming functions |
| CN108635516A (en) * | 2018-05-15 | 2018-10-12 | 深圳市鑫永康生物技术开发有限公司 | A kind of formula and preparation method thereof adjusting blood glucose, blood fat particle electuary |
| CN108850913A (en) * | 2018-06-04 | 2018-11-23 | 山东龙力生物科技股份有限公司 | One kind special medicine purposes formula food of diabetes containing prebiotics and preparation method thereof |
| CN110432500A (en) * | 2019-08-07 | 2019-11-12 | 武汉英纽林生物科技有限公司 | A kind of prebiotic compositions and preparation method and purposes containing inulin |
| CN112042753A (en) * | 2020-09-16 | 2020-12-08 | 甘肃华羚乳品股份有限公司 | Modified milk powder suitable for diabetes patients and preparation method thereof |
| CN113508841A (en) * | 2021-07-09 | 2021-10-19 | 遂宁市生岁食用植物油有限公司 | Nutritious morning tea |
| CN113575694A (en) * | 2021-07-15 | 2021-11-02 | 黑龙江谱华威乳业集团有限公司 | Low-fat modified milk powder containing composition for assisting in reducing blood fat and lowering blood pressure |
| CN113951328A (en) * | 2021-11-30 | 2022-01-21 | 北安宜品努卡乳业有限公司 | A nutritional food for lowering blood sugar and reducing blood lipid, and its preparation method |
| CN114145457A (en) * | 2021-12-10 | 2022-03-08 | 黑龙江飞鹤乳业有限公司 | Hypoglycemic composition |
| WO2023104181A1 (en) * | 2021-12-10 | 2023-06-15 | 黑龙江飞鹤乳业有限公司 | Hypoglycemic composition |
| CN116420875A (en) * | 2023-02-06 | 2023-07-14 | 黑龙江飞鹤乳业有限公司 | Nutritional composition for assisting blood lipid regulation and cardiovascular and cerebrovascular health |
| CN116420875B (en) * | 2023-02-06 | 2024-03-15 | 黑龙江飞鹤乳业有限公司 | Nutritional composition for assisting blood lipid regulation and cardiovascular and cerebrovascular health |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105394182A (en) | Nutritional steamed stuffed bun with blood sugar reducing and heart and cerebral vessel health promoting efficacy | |
| CN102348469B (en) | Omega-3 enriched fish oil-in-water parenteral nutrition emulsions | |
| CN104619197B (en) | Metabolic imprinting effect with the nutrients comprising butter oil and the big lipid globule of plant fat | |
| CN102065699A (en) | Lipid-containing compositions and methods of use thereof | |
| TWI519243B (en) | Liquid diet | |
| CN105394748A (en) | Method and composition for nutritionally improving glucose control and insulin action | |
| CN108041605A (en) | The Metabolic imprinting effect of the lipid composition specially designed | |
| US20090311367A1 (en) | Dietary Supplement | |
| CN102429307A (en) | Low-calorie and total-nutrient beverage and preparation method thereof | |
| CN109077124A (en) | A kind of high fat diet Weight reducing compound and its application | |
| CN102205011A (en) | Medicinal composition with weight loss function | |
| CN105249175A (en) | Whole nutrition powder capable of conditioning diet and diseases and preparation method thereof | |
| Carr et al. | Food components that reduce cholesterol absorption | |
| WO2014204382A1 (en) | Administration of a food composition product | |
| Bandali et al. | The influence of dietary fat and intestinal pH on calcium bioaccessibility: an in vitro study | |
| CN105853467B (en) | Lactobacillus reuteri GMNL-263 is used to prepare the purposes of blood-fat reducing composition | |
| WO2009135959A1 (en) | Food product for enterally or orally feeding diabetic patients | |
| US20070248621A1 (en) | Food product containing policosanols | |
| US20040096527A1 (en) | Compositions for lowering serum cholesterol level | |
| CN105311035B (en) | The application of phytosterol or/and phytosterin ester in uric acid control | |
| US20120184760A1 (en) | Removal of monoglycerides from fatty acid concentrates | |
| CN104055947A (en) | Traditional Chinese medicine composition comprising grape extract products and preparation method thereof | |
| KR100966719B1 (en) | Composition comprising Orostachys japonicus extract for inhibiting obesity and for preventing or treating hyperlipidemia | |
| JP2008161077A (en) | Functional food with blood flowability improving effect | |
| US20110053888A1 (en) | Mixture Of Carboyhydrates And Its Use In The Preparation Of A Product Intended For Oral Or Enteral Nutrition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160316 |
|
| WD01 | Invention patent application deemed withdrawn after publication |